Cartesian Insider Sales Reveal Confidence, Not Crisis – How the Deal Impacts Its RNA‑Cell Therapy Outlook
Cartesian Therapeutics insider sales on Jan 6, 2026 show routine RSU releases amid a strong 30 % insider stake; clinical data from RNA‑CAR‑T trials hint at breakthrough potential while stock rebounds from a 51 % YTD drop.
3 minutes to read